Veeva Systems projected at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, that its AI product lineup and a new horizontal customer relationship management offering would help the company reach $6 billion in revenue by 2030.
The target, set roughly two years ago, was calculated based primarily on existing core life sciences products and does not include assumed contributions from AI offerings or the Aspen CRM platform, said Paul Shawah, executive vice president of strategy at Veeva. The company's current annual revenue run rate stands at $3.46 billion, growing at a rate of 16.5%.
"Our opportunity is not only to deliver the next generation of platform and technology, but also to be a more friendly company, a more transparent company, to be easier to do business with," Shawah said of the horizontal CRM push aimed at non-life-sciences organizations seeking faster implementation and lower cost.
Veeva is rolling out two distinct AI products. Vault AI, which carries consumption-based pricing tied to token usage, assists users across the platform with summarization, acceleration and decision support. Falcon is positioned as an agentic labor tool designed to perform substantive work such as document processing, medical literature review and health authority communications; its pricing may shift toward outcome-based models or enterprise license agreements.
Falcon MLR, derived from Veeva's acquisition of Compli six years prior, adds an agentic layer to commercial content workflows and review and approval processes. The company's gross margins remain near 75%.
In life sciences CRM, Vault CRM reported its strongest quarter on record, highlighted by large customer decisions from Eli Lilly, Biogen and Regeneron. One top-20 pharmaceutical company deployed an agentic call report across its entire U.S. field force. Twelve of the top 20 pharmaceutical companies now use Veeva CRM, with only two account decisions still outstanding. Six of the top 20 were previously lost to Salesforce, and Veeva's win rate against competitors outside the top 20 exceeds 80%. Management expects to maintain more than 70% long-term market share in CRM, with more than 180 customers currently live on the Vault CRM platform.
Shawah emphasized the commercial impact of regulatory speed. "Getting that drug into market 30 days or 60 days or 90 days faster can get that drug to patients that need it sooner, but it also creates a significant revenue opportunity," he said, noting that cutting health authority approval timelines by 30 to 90 days could translate into millions of dollars in added revenue per blockbuster drug.
The contract research organization channel was identified as a potential $1 billion opportunity over time. Veeva's broader commercial and data portfolio includes Crossix for measurement and audience analytics, Link Key People for key people data, and Compass for patient and prescriber data. Its R&D suite spans clinical, quality, regulatory and safety software alongside newer products including EDC, Safety, RTSM and eCOA.
Veeva has a market capitalization of approximately $42.5 billion.
